An in-silico approach for drug repositioning to tumour anti-migration using an integrated genomic strategy

Yong Mao, Kemi Cui, Wang Lulu, Hong Zhao, Fang Nie, Miriam Brandl, Dominik Beck, Liang Gao, Stephen Wong

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Cell migration is a key step for deterioration of many in situ or metastasis malignant tumours. Tumour anti-migration is a promising strategy to treat cancer, but corresponding drugs developed under such a strategy are still in dire poverty, partly due to the lengthly process of drug trials and approval required by the US Food and Drug Administration (FDA). Given there are thousands of FDA approved drugs in the market, we believe that drug repositioning may provide a fast and cost-effective way to identify potential anti-migration drugs. In this paper, an in-silico drug screening method using a genomic strategy is proposed for the goal, in which genomic signature identification combined with support vector machine modelling is adopted to estimate drug efficacy. And a high-throughput, sensitive, 3-dimensional invasion assay by quantitative bioluminescence imaging proved the performance of proposed method on in vitro disease models.

Original languageEnglish (US)
Title of host publicationProceedings of the 2011 IEEE/NIH Life Science Systems and Applications Workshop, LiSSA 2011
Pages88-91
Number of pages4
DOIs
StatePublished - 2011
Event2011 IEEE/NIH Life Science Systems and Applications Workshop, LiSSA 2011 - Bethesda, MD, United States
Duration: Apr 7 2011Apr 8 2011

Publication series

NameProceedings of the 2011 IEEE/NIH Life Science Systems and Applications Workshop, LiSSA 2011

Other

Other2011 IEEE/NIH Life Science Systems and Applications Workshop, LiSSA 2011
CountryUnited States
CityBethesda, MD
Period4/7/114/8/11

ASJC Scopus subject areas

  • Life-span and Life-course Studies

Fingerprint Dive into the research topics of 'An in-silico approach for drug repositioning to tumour anti-migration using an integrated genomic strategy'. Together they form a unique fingerprint.

Cite this